Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

REGENXBIO Completes Enrollment In ATMOSPHERE And ASCENT Pivotal Studies Evaluating Surabgene Lomparvovec In Wet AMD Using Subretinal Delivery

Author: Benzinga Newsdesk | October 06, 2025 07:10am
  • Over 1,200 participants enrolled in ATMOSPHERE® and ASCENT® pivotal trials, representing largest global gene therapy program ever conducted
  • Subretinal surabgene lomparvovec on track to be first gene therapy for wet AMD
  • Topline pivotal data expected in Q4 2026

ROCKVILLE, Md., Oct. 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the completion of enrollment in the ATMOSPHERE® and ASCENT® pivotal studies evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet age-related macular degeneration (wet AMD) using subretinal delivery.

Posted In: RGNX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist